Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evolent Health (EVH)
NYSE:EVH
Holding EVH?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.03Last Year’s EPS
$0.23Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -53.56%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Evolent's strong market position and record business signings, but was overshadowed by significant challenges related to increased medical costs, earnings shortfall, and the need for additional rate negotiations. Despite long-term growth expectations, the immediate financial performance and operational hurdles present a cautious outlook.Company Guidance
During the third quarter 2024 earnings call, Evolent Health provided a revised outlook, noting a shortfall in adjusted EBITDA, now expected to be between $160 million and $175 million for the year, due to unforeseen increases in medical expenses. These expenses, particularly in the Specialty Performance Suite, were approximately $42 million higher than forecasted, affecting the quarter's adjusted EBITDA, which stood at $31.8 million. The company faces challenges from a rapid increase in oncology costs, with $24 million in higher net expenses related to prior periods and an $18 million increase due to recent cost accelerations. Evolent is responding with several measures, including seeking an additional $100 million in annualized rate increases by January 2025, auditing new data for accuracy, and potentially shifting underperforming markets to a fee-based model. Despite these setbacks, Evolent remains optimistic about its long-term growth prospects, reaffirming a goal of 20% average annual adjusted EBITDA growth and 15% plus revenue growth.Record New Business Signings
Evolent announced 6 new revenue agreements in Q3 2024, the highest quarterly number in the company's history, bringing the total for the year to 17.
Strong Market Position
Evolent's market position remains strong with high demand for its solutions, evidenced by new agreements with major national payers and expansions with existing clients.
Cash Flow and Liquidity
Evolent remains well-capitalized with strong cash flow generation, reporting $18.7 million in cash from operations for Q3 2024.
Long-term Growth Expectations
Evolent reaffirmed its long-term expectations of growing annual adjusted EBITDA by at least 20% on average and revenue growth of 15% plus.
---
EVH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $24.57 | $13.36 | -45.62% |
| Aug 08, 2024 | $20.87 | $26.40 | +26.50% |
| May 09, 2024 | $26.96 | $24.46 | -9.27% |
| Feb 22, 2024 | $29.77 | $34.07 | +14.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evolent Health (EVH) report earnings?
Evolent Health (EVH) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Evolent Health (EVH) earnings time?
Evolent Health (EVH) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVH EPS forecast?
EVH EPS forecast for the fiscal quarter 2024 (Q4) is $0.03.
---